Clinical Trials Logo

Opiate Substitution Treatment clinical trials

View clinical trials related to Opiate Substitution Treatment.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05164549 Completed - Clinical trials for Opiate Substitution Treatment

Extended-release Pharmacotherapy for Opioid Use Disorder

EXPO
Start date: August 6, 2019
Phase: Phase 3
Study type: Interventional

The primary objective is a clinical superiority effectiveness contrast to standard of care. Reported following SPIRIT and CONSORT standards, the study will determine whether extended-release injectable depot Buprenorphine (XR-Bup) maintenance therapy for OUD over six months is clinically superior to standard-of-care, oral medication (sublingual Buprenorphine [SL-Bup] or oral methadone [Met]; together: Bup/Met)

NCT ID: NCT04199728 Completed - Clinical trials for Opioid-Related Disorders

Use of a GLP-1R Agonist to Treat Opioid Use Disorder

Start date: October 18, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This research is being done to find out if liraglutide (brand name is Saxenda®) can safely and effectively reduce craving for opioids in patients with opioid use disorder, a primary factor contributing to early relapse.

NCT ID: NCT02496403 Completed - Clinical trials for Opiate Substitution Treatment

Buprenorphine and Substance Abuse Services for Prescription Opioid Dependence

Start date: December 2015
Phase: N/A
Study type: Interventional

This is a randomized trial of two group-based models of care for buprenorphine/naloxone (bup/nx) patients in Substance Use (SU) specialty treatment: Standard Medical Management (SMM) and Intensive Outpatient Treatment (IOT). The setting is a large outpatient SU treatment program, where a medical management model of care has not been empirically tested with bup/nx patients, and where a high prevalence of patients with co-occurring psychiatric and medical co-morbidities are treated. SSM includes brief weekly group-based visits consistent with previously studied medical models, and is drawn from primary care bup/nx research. IOT is a predominant model of care in specialty treatment, and incorporates psychosocial support, 12-step, educational and relapse-prevention based approaches. The investigators will recruit 300 adult patients inducted onto bup/nx, randomize them to either SMM or IOT, and conduct telephone follow-up interviews at 6 and 12 months. Study investigators will examine the impact of these treatment approaches on 90-day bup/nx adherence, opioid and SU abstinence, quality of life, and health care and societal costs. Further, investigators will examine whether the effect of IOT versus SMM on adherence and SU treatment outcomes is greater for those with medical or psychiatric co-morbidities. This innovative approach includes a focus on complex patients with psychiatric and medical co-morbidities in specialty care, adapting a care model previously only tested in primary care, a 12-month follow-up, no research-forced medication taper, an examination of health care and societal costs, and a combination of patient self-report and electronic medical record data. Through this approach, the proposed study will yield critically important findings on how best to treat complex prescription opioid dependent patients with an integrative behavioral services and medication treatment model in SU treatment.